Skip Navigation


NDT Plus Advance Access originally published online on April 5, 2008
NDT Plus 2008 1(4):241-243; doi:10.1093/ndtplus/sfn027
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
1/4/241    most recent
sfn027v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Shores, N. J.
Right arrow Articles by Kimberly, J.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Seronegative hepatitis C-related fibrosing cholestatic hepatitis after renal transplant: a case report and review of the literature

Nathan J. Shores and James Kimberly

Section of Gastroenterology, Department of Internal Medicine, Wake Forest University Health System, Winston-Salem, NC, USA

Correspondence: Nathan J. Shores, Section of Gastroenterology, Department of Internal Medicine, Wake Forest University Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157, USA. Tel: +1-336-716-1114; Fax: +1-336-713-7312; E-mail: NShores@wfubmc.edu

Key Words: cholestasis • cirrhosis • hepatic fibrosis • hepatitis C • renal transplant

Received for publication January 30, 2008. Accepted for publication February 21, 2008.

The first 10% of the full text of this article appears below.


   Case
 
Ms J is a 52-year-old female who underwent deceased donor renal transplant (RT) in May 2006 for membranous glomerulonephritis after 6 years on haemodialysis. She was initially treated post-transplant with alemtuzumab (Campath) secondary to delayed graft function and was subsequently discharged on tacrolimus, mycophenolate and prednisone for chronic immunosuppression. Ms J tested negative for anti-HCV in her first transplant consultation in 2004 and again just 12 days prior to surgery. Her bilirubin (0.5 mg/dL), alkaline phosphatase (ALP 94 IU/L), aspartate aminotransferase (AST 28 IU/L) and alanine aminotransferase (ALT 14 IU/L) were all . . . [Full Text of this Article]


   Discussion
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?